Retatrutide clinical trial data Retatrutide data comes primarily from two sources: a Phase 2 trial published in the New England Journal of Medicine and the Phase 3 TRIUMPH program that began reporting results in mid-2025
The global nasal drug delivery market encompasses prescription products such as intranasal corticosteroids, antihistamines, and decongestants
It was originally developed for anxiety and cognitive enhancement, but its immune-modulating properties make it relevant to autoimmune conditions with neuropsychiatric components
In a cellular model of dopamine neurotoxicity induced by fisetinone, silencing of PGC-1 expression was found to significantly increase the protein expression levels of PINK1, parkin, and their phosphorylated proteins (Peng et al., 2019)
It induces satiety and slows gastric emptying by acting on regions of the brain and restoring sensitivity to the hormone leptin [15], [16]
Per ProHealth's published guarantee terms, the company offers a 100-day money-back guarantee on its products